Guardant Health Stock

Guardant Health ROCE

The Return on Capital Employed (ROCE) of Guardant Health (GH) as of Aug 22, 2026 is 440.30 %. In the previous year, Return on Capital Employed (ROCE) was 317.65 % — a change of 38.61% (higher).

ROCE

440.30 %

YoY

38.61%

Last updated:

In 2026, Guardant Health's return on capital employed (ROCE) was 440.30 %, a 38.61% increase from the 317.65 % ROCE in the previous year.

The Guardant Health ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-17.70 USD
Jan 1, 2019
-9.71 USD
Jan 1, 2020
-18.81 USD
Jan 1, 2021
-63.72 USD
Jan 1, 2022
-904.58 USD
Jan 1, 2023
-355.88 USD
Jan 1, 2024
317.65 USD
Jan 1, 2025
440.30 USD
The Guardant Health ROCE history
YEARROCEYoY
440.30 %+38.61%
317.65 %-189.26%
-355.88 %-60.66%
-904.58 %+1,319.61%
-63.72 %+238.81%
-18.81 %+93.62%
-9.71 %-45.14%
-17.70 %-33.97%
-26.81 %-51.27%
-55.02 %
Access this data via the Eulerpool API

Guardant Health Stock analysis

What does Guardant Health do? Guardant Health Inc is an American company specializing in the development of non-invasive diagnostic tests for cancer. The company was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz. The two founders had previously successfully founded a company specialized in the development of blood tests for pregnancies. Guardant Health's goal is to detect traces of cancer cells in the blood of patients to enable early cancer diagnosis. Based on the liquid biopsy tests offered by the company, doctors can identify tumor cells and genetic mutations without relying on invasive methods such as tissue sampling. This allows for faster diagnosis and quicker treatment decision-making. Guardant Health's business model is based on the commercialization of its liquid biopsy tests, which are based on specially developed DNA sequencing methods. The company offers both diagnostic tests that can aid in cancer identification, as well as tests that can help doctors monitor the success of cancer therapies. Guardant Health has directed its offerings towards multiple products and divisions, including Guardant360, GuardantOmni, and GuardantReveal. Each of these products aims to solve specific challenges related to cancer diagnosis and treatment. Guardant360 is a diagnostic test specifically developed to help doctors sequence the DNA of cancer cells in the blood of patients and identify the genetic changes contributing to tumor growth. On the other hand, GuardantOmni is a liquid biopsy test that targets a broader range of cancer types. It enables a comprehensive genetic scan of cancer cells in the blood to identify specific mutations that can aid in tracking disease progression and selecting appropriate therapies. GuardantReveal is a test aimed at monitoring patients at higher risk of cancer. The test can be used to detect early signs of tumors in patients who are at higher risk due to their family history, age, or other factors. Guardant Health has achieved considerable success in the field of liquid biopsy detection in recent years. Currently, more than 100,000 patients worldwide have access to Guardant Health's liquid biopsy-based tests. The company is based in Redwood City, California, and employs over 1,000 employees. It has a broad investor base, including The SoftBank Vision Fund, Sequoia Capital, Lightspeed Venture Partners, and Khosla Ventures. Overall, the company has raised over $550 million in funding. Guardant Health aims to revolutionize the world of cancer diagnostics and treatment. By radically changing the process of diagnosing and monitoring cancer patients, the company aims to improve the survival rate of cancer patients and make cancer treatment more effective overall. Guardant Health is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Guardant Health's Return on Capital Employed (ROCE)

Guardant Health's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Guardant Health's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Guardant Health's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Guardant Health’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Guardant Health stock

Return on Capital Employed (ROCE) of Guardant Health is 440.30 % in 2026.

Return on Capital Employed (ROCE) of Guardant Health changed from 317.65 % to 440.30 %, representing a 38.61% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Guardant Health since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Guardant Health with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

Profitability — Guardant Health

All Key Metrics — Guardant Health